Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 26;42(7):1897–1911. doi: 10.1148/rg.220045

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the Radiological Society of North America, Inc.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Type 5 lymph node in a 63-year-old BRCA2 mutation carrier with a palpable lump in the left axilla 9 days after receiving the first dose of the Moderna SARS-CoV-2 vaccine in the left arm. In 2006, she underwent left mastectomy for invasive ductal carcinoma. US image shows a type 5 lymph node (arrow), which has associated hyperemia on a power Doppler image (inset) (BI-RADS 4). US-guided core biopsy yielded reactive follicular hyperplasia. — Type 5 lymph node in a 63-year-old BRCA2 mutation carrier with a palpable lump in the left axilla 9 days after receiving the first dose of the Moderna SARS-CoV-2 vaccine in the left arm. In 2006, she underwent left mastectomy for invasive ductal carcinoma. US image shows a type 5 lymph node (arrow), which has associated hyperemia on a power Doppler image (inset) (BI-RADS 4). US-guided core biopsy yielded reactive follicular hyperplasia.